RENO, NV, Sept. 22 /PRNewswire-FirstCall/ -- ChromoCure, Inc. (PINKSHEETS: KKUR) announced today it has appointed Mikhail Kantius, MD to its Advisory Board and business development team. Dr. Kantius will assist the company in forming strategic alliances as well as promote the company's technology and service to pathology labs throughout the Northeast United States. About Mikhail Kantius, M.D., F.C.A.P., Advisory Board and Lead Pathologist Trained and Board Certified Surgical Pathologist/Dermatopathologist. He brings a 20 year career of experience as Medical Director/ Administrator/Surgical Pathologist and Dermatopathologist in a privately owned commercial Pathology Laboratory. His early research interests were involved in Tissue culture and Cytogenetics. He holds unrestricted licenses to practice in state of NY, NJ, Florida and Maine. Shareholders will soon receive updates on the following: - Announcement of joint research and development agreement - Initial scanner installations with diagnostic labs - Elimination of significant long-term liabilities and removal from the Balance Sheet. - Acquisition of profitable diagnostic labs to expand the company's operations - Release of technology and industry White Papers. About ChromoCure ChromoCure develops and provides proprietary cancer detection systems. The Company owns its technology and provides its systems on a revenue sharing basis. The Company's systems measure the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company believes its technology has an effective accuracy of 100% for all cancers at all stages. The Company believes its technology superior and will become the gold standard for cancer detection worldwide. The Company's technology and understanding of cancer also suggest non-toxic and non-invasive approaches to cancer therapy and cure research. The Company will release progress reports on these initiatives from time to time. Safe-Harbor Statement This release contains statements or projections regarding future performance that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision. DATASOURCE: ChromoCure, Inc. CONTACT: Investor Relations: Contact: ChromoCure, Inc., , Tel (775) 636-6548

Copyright